Brazil Allow CBD Oil for Multiple Sclerosis Patients
Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, subsidiary, HempMeds® Brasil today announced that the Brazilian government has authorized a doctor’s prescription for the Company’s hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis.
This marks the first time that Brazil’s National Health Surveillance Agency ANVISA has granted the filling of a prescription for RSHO™ to specifically help patients combat the effects of Multiple Sclerosis. Per the Multiple Sclerosis International Federation (MSIF), more than 2.5 million people worldwide are affected by MS, a progressive disease of the central nervous system, for which there is currently no cure. In Brazil, MS prevalence is estimated to range from 1.36-20 per 100,000 inhabitants.
“We commend the Brazilian government for recognizing nationwide health problems that exist, including Multiple Sclerosis and a multitude of other chronic medical conditions, and looking for solutions that can help alleviate those problems,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “Brazil has embraced the therapeutic value of medical cannabinoids and is helping its people treat the symptoms of certain conditions with no known cure or limited treatment options.”
“Research findings suggest that cannabis could slow the neurodegenerative process of MS and help patients manage the symptoms associated with their disease,” added Dr. Titus. “For instance, one study showed cannabinoids demonstrated neuroprotective effects during an animal model of MS, reducing the damage to myelin caused from inflammation, while in another study MS patients saw significant improvements in muscle spasticity and reduced sleep disturbances after four weeks of cannabis treatments.”
“While our pharmaceutical development investment company, AXIM Biotech is researching a novel chewing gum delivery method involving cannabinoids to specifically treat pain and muscular spasticity in MS patients in European markets; a natural botanical CBD product is now available via HempMeds Brazil to potentially address some of the challenges that MS patients in Brazil are facing,” Dr. Titus further expressed. “Although perhaps not as therapy specific as the pharmaceutically developed version, our natural botanical product may have benefit for improved quality of life for these medically challenged Brazilian patients.”
In May 2015, HempMeds® Brasil became the first company to offer legal medicinal cannabis products to Brazil after receiving import approval for those suffering from specific medical conditions. The Brazilian government now waives import taxes for RSHO™, subsidizes its cost and covers the product under the Country’s health insurance.
This article was initially published on Financial Content
Patients often substitute medical marijuana for opioid pain medications and other drugs
Medical marijuana patients tend to reduce their use of prescription opioid pain medications, accordi…
Cannabinoids used in Sequence with Chemotherapy are a more Effective Treatment for Cancer
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in k…
Cannabis Extracts Associated With Reduced ADHD Symptoms
The administration of whole-plant cannabis extracts is associated with improvements in cognition and…
Veteran Says Medical Marijuana Controls His PTSD Symptoms: Wants Cannabis For All Vets
Some of the latest statistics show that somewhere around 20 percent of the military veterans that se…
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior
Cannabidiol (CBD), one of the main components of Cannabis sp., presents clinical and preclinical anx…
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as…